These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 14642644)
1. Memantine attenuates the increase in striatal preproenkephalin mRNA expression and development of haloperidol-induced persistent oral dyskinesias in rats. Andreassen OA; Waage J; Finsen B; Jørgensen HA Brain Res; 2003 Dec; 994(2):188-92. PubMed ID: 14642644 [TBL] [Abstract][Full Text] [Related]
2. The relationship between oral dyskinesias produced by long-term haloperidol treatment, the density of striatal preproenkephalin messenger RNA and enkephalin peptide, and the number of striatal neurons expressing preproenkephalin messenger RNA in rats. Andreassen OA; Finsen B; Ostergaard K; Sørensen JC; West MJ; Jørgensen HA Neuroscience; 1999 Jan; 88(1):27-35. PubMed ID: 10051187 [TBL] [Abstract][Full Text] [Related]
3. Inhibition by memantine of the development of persistent oral dyskinesias induced by long-term haloperidol treatment of rats. Andreassen OA; Aamo TO; Jøorgensen HA Br J Pharmacol; 1996 Oct; 119(4):751-7. PubMed ID: 8904651 [TBL] [Abstract][Full Text] [Related]
4. Alterations in mRNA levels of D2 receptors and neuropeptides in striatonigral and striatopallidal neurons of rats with neuroleptic-induced dyskinesias. Egan MF; Hurd Y; Hyde TM; Weinberger DR; Wyatt RJ; Kleinman JE Synapse; 1994 Nov; 18(3):178-89. PubMed ID: 7531873 [TBL] [Abstract][Full Text] [Related]
5. No changes in dopamine D(1) receptor mRNA expressing neurons in the dorsal striatum of rats with oral movements induced by long-term haloperidol administration. Petersen R; Finsen B; Andreassen OA; Zimmer J; Jørgensen HA Brain Res; 2000 Mar; 859(2):394-7. PubMed ID: 10719094 [TBL] [Abstract][Full Text] [Related]
6. Pharmacological and neurochemical differences between acute and tardive vacuous chewing movements induced by haloperidol. Egan MF; Hurd Y; Ferguson J; Bachus SE; Hamid EH; Hyde TM Psychopharmacology (Berl); 1996 Oct; 127(4):337-45. PubMed ID: 8923569 [TBL] [Abstract][Full Text] [Related]
7. Oral dyskinesias and morphological changes in rat striatum during long-term haloperidol administration. Andreassen OA; Meshul CK; Moore C; Jørgensen HA Psychopharmacology (Berl); 2001 Aug; 157(1):11-9. PubMed ID: 11512038 [TBL] [Abstract][Full Text] [Related]
8. Oral Dyskinesias and striatal lesions in rats after long-term co-treatment with haloperidol and 3-nitropropionic acid. Andreassen OA; Ferrante RJ; Beal MF; Jørgensen HA Neuroscience; 1998 Dec; 87(3):639-48. PubMed ID: 9758230 [TBL] [Abstract][Full Text] [Related]
9. Failure to down regulate NMDA receptors in the striatum and nucleus accumbens associated with neuroleptic-induced dyskinesia. Hamid EH; Hyde TM; Baca SM; Egan MF Brain Res; 1998 Jun; 796(1-2):291-5. PubMed ID: 9689480 [TBL] [Abstract][Full Text] [Related]
10. Oral dyskinesias and histopathological alterations in substantia nigra after long-term haloperidol treatment of old rats. Andreassen OA; Ferrante RJ; Aamo TO; Beal MF; Jørgensen HA Neuroscience; 2003; 122(3):717-25. PubMed ID: 14622915 [TBL] [Abstract][Full Text] [Related]
11. Electron spin resonance spectroscopy reveals alpha-phenyl-N-tert-butylnitrone spin-traps free radicals in rat striatum and prevents haloperidol-induced vacuous chewing movements in the rat model of human tardive dyskinesia. Rogoza RM; Fairfax DF; Henry P; N-Marandi S; Khan RF; Gupta SK; Mishra RK Synapse; 2004 Dec; 54(3):156-63. PubMed ID: 15452862 [TBL] [Abstract][Full Text] [Related]
12. Role of aging and striatal nitric oxide synthase activity in an animal model of tardive dyskinesia. Harvey BH; Nel A Brain Res Bull; 2003 Aug; 61(4):407-16. PubMed ID: 12909284 [TBL] [Abstract][Full Text] [Related]
13. The role of metabotropic glutamate receptors in regulation of striatal proenkephalin expression: implications for the therapy of Parkinson's disease. Wardas J; Pietraszek M; Wolfarth S; Ossowska K Neuroscience; 2003; 122(3):747-56. PubMed ID: 14622918 [TBL] [Abstract][Full Text] [Related]
14. GM1 ganglioside attenuates the development of vacuous chewing movements induced by long-term haloperidol treatment of rats. Andreassen OA; Jørgensen HA Psychopharmacology (Berl); 1994 Dec; 116(4):517-22. PubMed ID: 7701057 [TBL] [Abstract][Full Text] [Related]
15. Excitatory mechanisms in neuroleptic-induced vacuous chewing movements (VCMs): possible involvement of calcium and nitric oxide. Naidu PS; Kulkarni SK Behav Pharmacol; 2001 Jun; 12(3):209-16. PubMed ID: 11485057 [TBL] [Abstract][Full Text] [Related]
16. Correlation of vacuous chewing movements with morphological changes in rats following 1-year treatment with haloperidol. Meshul CK; Andreassen OA; Allen C; Jørgensen HA Psychopharmacology (Berl); 1996 Jun; 125(3):238-47. PubMed ID: 8815959 [TBL] [Abstract][Full Text] [Related]
17. Central administration of the neurotensin receptor antagonist SR48692 attenuates vacuous chewing movements in a rodent model of tardive dyskinesia. McCormick SE; Stoessl AJ Neuroscience; 2003; 119(2):547-55. PubMed ID: 12770567 [TBL] [Abstract][Full Text] [Related]
18. Ultrastructural correlates of haloperidol-induced oral dyskinesias in rats: a study of unlabeled and enkephalin-labeled striatal terminals. Roberts RC; Lapidus B J Neural Transm (Vienna); 2003 Sep; 110(9):961-75. PubMed ID: 12938022 [TBL] [Abstract][Full Text] [Related]
19. Modulatory effect of neurosteroids in haloperidol-induced vacuous chewing movements and related behaviors. Bishnoi M; Chopra K; Kulkarni SK Psychopharmacology (Berl); 2008 Feb; 196(2):243-54. PubMed ID: 17955214 [TBL] [Abstract][Full Text] [Related]